Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism GSK-3β inhibitors(Glycogen synthase kinase-3 beta inhibitors), Sp1 inhibitors(Transcription factor Sp1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Preclinical | United States | 19 Dec 2023 | |
| Brain Injuries, Traumatic | Preclinical | United States | 19 Dec 2023 | |
| Huntington Disease | Preclinical | United States | 19 Dec 2023 | |
| Supranuclear Palsy, Progressive | Preclinical | United States | 19 Dec 2023 |





